Dossier assessment

Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A19-49
Last updated

Report documents

  1. Extract of dossier assessment

    Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 135 kB, EN, not accessible
  2. Dossier assessment

    Empagliflozin/linagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 352 kB, DE, not accessible

Dossier assessment

Indication:

Adults with type 2 diabetes mellitus when diet and exercise plus at least 2 blood-glucose lowering drugs (except insulin, here metformin/sulphonylurea and empagliflozin/linagliptin) do not provide adequate glycaemic control

Result of dossier assessment:

Added benefit not proven due to a lack of suitable study data

Additional information

Federal Joint Committee (G-BA)

2019-11-22 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A19-49
Commission
Commission awarded on 29.05.2019 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Digestion, metabolism and hormones
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form